X. Zeng

发表

Cryptococcosis manifesting as isolated biliary infection: Case report and brief review of literature.

Min Wang, Hua-ying Zhou, Shengqiao Shi, 2017, Clinics and research in hepatology and gastroenterology.

Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA

Chongqing Tan, X. Wan, Xiaohui Zeng, 2022, Advances in Therapy.

Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%

Chongqing Tan, Liubao Peng, X. Wan, 2021, Advances in Therapy.

Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China

Chongqing Tan, Liubao Peng, Lidan Yi, 2019, Advances in Therapy.

Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China

Gaoyun Hu, Chongqing Tan, X. Wan, 2019, Clinical Drug Investigation.

Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis

Chongqing Tan, Liubao Peng, Lidan Yi, 2021, Clinical Rheumatology.

Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

Chongqing Tan, Lidan Yi, X. Wan, 2021, Advances in Therapy.

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer

Qiong Lu, Chongqing Tan, Liubao Peng, 2013, PloS one.

The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience

J. Karnon, Bin Wu, Liubao Peng, 2012, PloS one.

Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

Chongqing Tan, Qiao Liu, X. Luo, 2021, Advances in Therapy.

First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis

Chongqing Tan, Liubao Peng, X. Wan, 2019, Cancer.

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis

Chongqing Tan, Liubao Peng, X. Wan, 2019, JAMA oncology.

Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis

Qiong Lu, Chongqing Tan, Liubao Peng, 2014, PloS one.

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma

Qiao Liu, Xiaohui Zeng, Chunjiang Wang, 2022, BMJ Open.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

Qijian Deng, Chongqing Tan, Qiao Liu, 2021, Frontiers in Pharmacology.

Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer From the US and Chinese Perspectives.

Haijun Deng, Chongqing Tan, Liubao Peng, 2019, Clinical therapeutics.

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Chongqing Tan, Qiao Liu, Liubao Peng, 2019, Clinical Drug Investigation.

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China

Chongqing Tan, Qiao Liu, Liubao Peng, 2020, BMJ Open.